Vancouver, British Columbia--(Newsfile Corp. - November 8, 2022) - Algernon Pharmaceuticals (CSE: AGN) (OTCQB: AGNPF) – The company is focused on the disease area of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and chronic kidney disease. Algernon was recently granted permission to conduct a Phase 1 clinical study of DMT for the treatment of stroke.
If you cannot view the video above, please visit:
Algernon Pharmaceuticals (CSE: AGN) (OTCQB: AGNPF)
About CEO Clips:
CEO Clips – are short company video profiles broadcast to a large audience of investors on TV and 15+ financial sites including Reuters, Yahoo!Finance, and Wall Street Journal.
BTV – Business Television/CEO Clips
Discover Companies to Invest in
Contact: Trina Schlingmann (604) 664-7401 x 5 email@example.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/143122